Pharma BD Deal Intelligence

Eli Lilly and Company / AurKa Pharma Inc.

2019 · Acquisition/Merger · $575M · Complete

Eli Lilly acquired AurKa Pharma, gaining the Aurora A kinase inhibitor AK-01 (LY3295668) for solid tumors. Total deal value up to $575M with $110M upfront and $465M in development and regulatory milestones.

Key facts

• Announced Jun 17, 2019
• Deal value $575M
• Deal type Acquisition/Merger
• Therapeutic area Solid tumors (small cell lung cancer)
• Indications Solid tumors (small cell lung cancer)
• Key assets AK-01 (LY3295668)
• Mechanism Aurora A kinase inhibitor

← Browse all deals  ·  How we score deals